DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $140.33.

A number of research firms recently issued reports on DXCM. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Finally, Redburn Atlantic assumed coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of DexCom stock in a transaction on Monday, April 8th. The stock was sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 427 shares of DexCom stock in a transaction on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at $8,729,648.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,735 shares of company stock valued at $7,619,347. Insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Capital World Investors raised its holdings in DexCom by 130.7% in the 4th quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Norges Bank bought a new position in shares of DexCom in the 4th quarter valued at $540,178,000. Artisan Partners Limited Partnership increased its stake in shares of DexCom by 164.8% in the 4th quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Capital Research Global Investors increased its stake in shares of DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA bought a new position in shares of DexCom in the 4th quarter valued at $231,773,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Down 1.0 %

NASDAQ DXCM opened at $113.38 on Friday. The firm has a market cap of $45.09 billion, a P/E ratio of 73.15, a P/E/G ratio of 2.77 and a beta of 1.22. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The stock’s 50-day moving average is $123.14 and its 200-day moving average is $125.66. DexCom has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Sell-side analysts anticipate that DexCom will post 1.78 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.